Vivoryon Therapeutics Reveals Upcoming Events for Investors

Vivoryon Therapeutics Reveals Upcoming Events for Investors

Vivoryon Therapeutics N.V. is poised to engage with investors at several forthcoming conferences, marking an exciting opportunity to share insights about its pioneering work in tackling inflammatory and fibrotic disorders, particularly emphasizing kidney diseases.

Upcoming Investor Conferences

As part of its commitment to investor engagement, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; Nasdaq: VVY) has lined up participation in the following key conferences:

mwb online Health Care Conference

Date: July 1, 2025
Presentation Time: 12:00 pm CEST
Presenters: Frank Weber, CEO; Julia Neugebauer, COO
This virtual conference will feature key insights into the company's innovative approaches in the health care sector.

H.C. Wainwright 4th Annual Kidney Virtual Conference

Date: July 14, 2025
Presentation Time: 3:00 pm CEST / 9:00 am EDT
Presenters: Frank Weber, CEO; Julia Neugebauer, COO
This event will also be virtual and will delve into the groundbreaking developments Vivoryon is pursuing to combat kidney ailments.

About Vivoryon Therapeutics N.V.

Vivoryon is on the cutting-edge of biotechnology, focusing on the development of small molecule medicines designed to treat severe conditions related to inflammation and fibrosis, primarily targeting the kidneys. The company's passion for science fuels its mission to transform patient outcomes by addressing critical health challenges through innovative medications.

Their lead program, varoglutamstat, represents a significant advancement in the treatment of diabetic kidney disease. As an orally available QPCT/L inhibitor, varoglutamstat is a part of Vivoryon's strategic focus to play a pivotal role in changing the management of kidney diseases, offering hope for improved patient care.

Exploring Vivoryon's Innovations

Vivoryon’s commitment goes beyond immediate medical needs; it involves a strategic vision for enhancing therapeutic assessments and outcomes for patients suffering from chronic kidney issues. The company employs an innovative approach, combining dedicated research and development efforts that aim to understand disease mechanisms at a deeper level.

This pursuit of knowledge underpins their research pipeline, which is rigorously designed to bring forward therapeutic options that tackle the complexities of kidney disorders. By embracing groundbreaking science, Vivoryon is not just aiming for treatment but for curing the source of chronic health problems.

Looking to the Future

The participation of Vivoryon in these investor conferences highlights not only its transparency with stakeholders but also its strategic approach to disseminate valuable information about its research progress and future projects. Investors are encouraged to tune into these presentations to gain unique insights directly from the leadership team.

Frequently Asked Questions

What is Vivoryon Therapeutics N.V. focused on?

Vivoryon is dedicated to developing innovative small molecule medicines aimed at treating inflammatory and fibrotic disorders, particularly those affecting the kidneys.

What are the upcoming events for Vivoryon?

Vivoryon will participate in the mwb online Health Care Conference on July 1, 2025, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025.

Who are the presenters at the investor conferences?

Frank Weber, CEO, and Julia Neugebauer, COO, will represent Vivoryon at both conferences, sharing insights into the company's advancements and research.

What is varoglutamstat?

Varoglutamstat is Vivoryon's flagship product, which is being evaluated for its potential to treat diabetic kidney disease as an orally available QPCT/L inhibitor.

How can I contact Vivoryon for more information?

For inquiries, you can reach out to Dr. Manuela Bader at IR@vivoryon.com or contact LifeSci Advisors for investor relations matters.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.